5 completed, 1 terminated. 3 Phase 3, 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow MC2-01 cream: new trials by email Literature Review of MC2-01 cream trials Research Report on MC2-01 cream
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel - Plaque Psoriasis | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 539 | 2025-12-30 | 2026-08-28 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects MC2-01 cream - Psoriasis Vulgaris | Phase 2 | Terminated | MC2 Therapeutics | 7 | 2018-12-27 | 2021-03-19 |
| This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream MC2-01 cream, Cal/BDP combination, Vehicle - Psoriasis Vulgaris | Phase 3 | Completed | MC2 Therapeutics | 498 | 2018-12-12 | 2020-12-16 |
| Evaluation of the Vasoconstriction Properties of MC2-01 Cream MC2-01 Cream, Clobetasol Propionate 0.05% Lotion, Betamethasone Dipropionate 0.05% Cream - Vasoconstriction | Phase 1 | Completed | MC2 Therapeutics | 36 | 2018-11-05 | 2020-01-09 |
| A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream MC2-01 Cream, CAL/BDP combination - Psoriasis Vulgaris | Phase 2 | Completed | MC2 Therapeutics | 63 | 2018-02-08 | 2019-12-24 |
| A Clinical Trial Evaluating Efficacy and Safety of MC2-01 Cream MC2-01 cream, Cal/BDP combination, Cream vehicle - Psoriasis Vulgaris | Phase 3 | Completed | MC2 Therapeutics | 794 | 2017-10-03 | 2024-12-09 |
MC2 Therapeutics (5) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1)
Czechia (2) · Germany (2) · United States (2) · China (1) · France (1)
Andreas Pinter, MD (1) · George Han (1) · Linda S. Gold, MD (1)
PMID 37490268, PMID 40274711, PMID 33852251, PMID 34648147, PMID 36050567